FR2578745A1 - BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS - Google Patents

BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS Download PDF

Info

Publication number
FR2578745A1
FR2578745A1 FR8503965A FR8503965A FR2578745A1 FR 2578745 A1 FR2578745 A1 FR 2578745A1 FR 8503965 A FR8503965 A FR 8503965A FR 8503965 A FR8503965 A FR 8503965A FR 2578745 A1 FR2578745 A1 FR 2578745A1
Authority
FR
France
Prior art keywords
medicament according
atrox
antiplatelet
antibodies
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8503965A
Other languages
French (fr)
Other versions
FR2578745B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR8503965A priority Critical patent/FR2578745B1/en
Priority to PCT/FR1986/000089 priority patent/WO1986005399A1/en
Priority to AU56257/86A priority patent/AU5625786A/en
Priority to EP86901898A priority patent/EP0215876A1/en
Publication of FR2578745A1 publication Critical patent/FR2578745A1/en
Application granted granted Critical
Publication of FR2578745B1 publication Critical patent/FR2578745B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present drugs are particularly intended to develop a blood fluidifying activity and are defined by the association of at least two constituents selected in different groups amongst the following groups. The platelet antiaggregants and(or) the anticoagulants; the antitissue antibodies and(or) the serums; the prior known substances as procoagulant substances.

Description

DESCRIPTION
Dans le but d'obtenir des produits développant notamment une activité pharmacologique antithrombosante plus complète gracie à l'association de produits ayant des sites d'action eomplémen taires ou différents , la présente innovation consiste à associer dans le meme médicament au moins deux constituants choisis dans un groupe parmi les groupessuivants:les anticoagulantset (ous) lesantiaggrégants plaquettaires;les sérums et (ou) anticorps antitissus;les venins et(ou) les toxines,les extraits tissulaires;les substances antérieurement connues en tant qu'agents procoagu-. DESCRIPTION
With the aim of obtaining products developing in particular a more complete antithrombotic pharmacological activity thanks to the association of products having eomplemenary or different sites of action, the present innovation consists in associating in the same medicament at least two constituents chosen from a group among the following groups: anticoagulants and (or) anti-aggregation platelets; serum and / or anti-tissue antibodies; venoms and (or) toxins, tissue extracts; substances previously known as procoagu- agents.

lantax
Citons à titre d'exemplas nom limitatifs:
-dans le groupe des antiaggrégants plaquettaires:l'acide acé tylsali cylique
-dans le groupe des anticoagulants:l'héparine
-dans le groupe des sérums et ou des anticorps antitissus:les sérums et(ou) anticorps antiplaquettes sanguines
-dans le groupe des venins et(ou) toxines::les venins de elaps corallinus,naja tripudians,naja nigricollxs,vipera aspis,vipera bitis,vipera daboia,vipera torva,crotalus horridus,laehesis mutus, lachesis alternatus,bothrops atrox atrox,scorpio europeus,scorpio palmatus,,prianurus austral s,,apis mellifica, apium virus,vespa crabro,vespa bombo,latrodectus mactansainsi que les extraits (par exemple:les fractions proteiques)des venins et toxines et(ou) les antisérums correspondants
-dairs le groupe des substances actuellement connues en tant que substances procoagulantes:la thrombime, la fibrine,le fibri.lantax
Let us quote as limiting examples of name:
-in the group of platelet antiaggregants: acetylsali cyclic acid
-in the group of anticoagulants: heparin
-in the group of sera and / or anti-tissue antibodies: sera and / or antibodies against blood platelets
-in the group of venoms and (or) toxins: the venoms of elaps corallinus, naja tripudians, naja nigricollxs, vipera aspis, vipera bitis, vipera daboia, vipera torva, crotalus horridus, laehesis mutus, lachesis alternatus, bothrops atrox atrox, scorpio europeus, scorpio palmatus ,, prianurus austral s ,, apis mellifica, apium virus, vespa crabro, vespa bombo, latrodectus mactans as well as extracts (for example: protein fractions) of venoms and toxins and (or) the corresponding antisera
-dairs the group of substances currently known as procoagulant substances: thrombime, fibrin, fibri.

nogène,les facteurs de coagulation,les phospholipides,les plaauettes,les extraits plaquetaires et autres activateurs de la
coagulation.nogen, coagulation factors, phospholipids, platelets, platelet extracts and other activators of
coagulation.

Les quelaues exemples non limitatifs donnés ci-aprés ne
font qu'illustrer l'innovation sans lalimiter..Ils ne consti
tuent que queques exemples particuliers.The non-limiting examples given below do not
only illustrate innovation without limiting it.
kill only a few specific examples.

Exemple I:
acide acétylsalicyliquet dose inférieure ou égale
à un gramme par jour)
venin de Bothrops lanceolatus
Exempel 2: acide acétylsalicylique
venin de bothrops lanceolatus
sérum (et-eu-anticorps)antiplaquettes sanguines
tes présentations de ces médicaments peuvent tre solides ou liquides sous toutesles formes pharmaceutiques possibles préparées selon les méthodes connues de 1' homme de l'art-Les principes actifs peuvent y êre incorposés à tous les véhicules et exci pients possibles employés dans les compositions pharmaceutiques
Les venins, les sérums, les anticorps, les substances procoagulan tes seront utilisés à une dilution supérieure ou égale à la troisième dilution décimale. Example I:
acetylsalicylic acid less or equal dose
to one gram per day)
venom of Bothrops lanceolatus
Example 2: acetylsalicylic acid
venom of bothrops lanceolatus
antiplatelet serum (and-had-antibody)
your presentations of these drugs can be solid or liquid in all possible pharmaceutical forms prepared according to methods known to those skilled in the art. The active principles can be incorporated into all of the possible vehicles and excipients employed in pharmaceutical compositions
The venoms, serums, antibodies, procoagulant substances will be used at a dilution greater than or equal to the third decimal dilution.

Claims (5)

REVENDICATIONS I-Médicament destiné à fluidifier le sang et (ou) à développer une activité antiinflammatoire et (ou) antalgique,earactérisé en ce qu'il est constitué par une association d'au moins deux constituants choisis dans un groupe différent parmm les groupes suivants:les antiaggrégants plaquettaires et (ou) lesanticoagulants, les sérums et (ou) les anticorps antitissus et (ou) les extraits tissulaires,les venins, les substances antérieurement connues comme agents procoagulants.CLAIMS I-Medication intended to thin the blood and / or to develop an anti-inflammatory and / or analgesic activity, earactérisé in that it is constituted by an association of at least two constituents chosen in a different group by mm the following groups : antiplatelet agents and / or anticoagulants, serums and / or anti-tissue antibodies and / or tissue extracts, venoms, substances previously known as procoagulant agents. 2-Médicament selon la revendication I caractérisé en ce qu'il contient un antiaggrégant plaquettaire (tel que par exemple 1' acide acétylsalicylique) et (ou) un anticoagulant(.tel que par exem ple l'héparine), associé(s) à un ou plusieurs vemin(s)(tels que le venin de bothrops atrox atrox ou oothrops lanceolatus,de lachésis mutus, de lachesis alternatus, naja nigricollis, crotalus horridus, crotalus cascavella, vipera aspis, apis mellifica, vespa crabro, vespa bombo, naja tripudians, lachesis neuwidii, vipera daboia vipera torva, vespa crabro, vespa bombo, latrodectus mactans, elaps corallinus) et (ou) aux extraits etfractions des venins et du aux antîsérums contre les . venins e-; (ou) leurs fractions.2-medicament according to claim I characterized in that it contains an antiplatelet agent (such as for example 1 acetylsalicylic acid) and (or) an anticoagulant (. Such as for example ple heparin), associated (s) with one or more vemin (s) (such as the venom of bothrops atrox atrox or oothrops lanceolatus, lachésis mutus, lachesis alternatus, naja nigricollis, crotalus horridus, crotalus cascavella, vipera aspis, apis mellifica, vespa crabro, vespa bombo na tripudians, lachesis neuwidii, vipera daboia vipera torva, vespa crabro, vespa bombo, latrodectus mactans, elaps corallinus) and (or) extracts and fractions of venoms and antisera against. venoms e-; (or) their fractions. 3-Médicament selon la revendication I caractérisé par l'association d'un antiaggrégant plaquéttaire tel que l'acide acétylsali- cylique avec le senin de bothrops lanceolatus.3-A medicament according to claim I characterized by the combination of an antiplatelet agent such as acetylsalicylic acid with the senin of bothrops lanceolatus. 4-Médicament selon la revendication I caractérisé par l'associa tiontion d'un antiaggrégant plaquettaire tel que acide acétyl -salicylique et (ou) un anticoagulant tel que l'héparine avec le venin bothrops atrox atrox et le sérum et(ou) les anticorps antiplaquettes sanguines 5-Médicament selon la revendication I caractérisé par l'association d'n antiaggrégant plaquettaire et (ou) un anticoagulant avec le sérum et(ou) les anticorps antiplaquettaire(s).4-medicament according to claim I characterized by the combination of an antiplatelet agent such as acetylsalicylic acid and (or) an anticoagulant such as heparin with the venom bothrops atrox atrox and the serum and (or) antibodies Blood antiplatelet 5-Medicament according to claim I characterized by the combination of an antiplatelet agent and / or an anticoagulant with the serum and / or the antiplatelet antibodies. 6-Médicament selon la revendication I caractérisé pr l'associas tion d'au moins un venin tel que le venin de bothrops atrox atrox et le sérum et (ou) les anticorps antiplaquettes sanguines 6-medicament according to claim I characterized pr the association of at least one venom such as the venom of bothrops atrox atrox and the serum and (or) antibodies to blood platelets REVENDICATIONS (suite) CLAIMS (cont'd) 7-Médicament selon la revendication I caractérisé en ce qu'il comprend une on plusieures substances) choisié(s) dans le groupe des substances connues antérieurement comme agents procoagulants telle(s) que par exemple:la fibrine,le fibrinogéne,lathrombine, les facteurs de coagulation,les plaquettes et leurs extraits collagène, les phospholipides,les inhibiteurs de la fibrinolyse. 7-medicament according to claim I characterized in that it comprises one or more substances) selected (s) from the group of substances previously known as procoagulant agents such as (s) such as for example: fibrin, fibrinogen, lathrombin, clotting factors, platelets and their collagen extracts, phospholipids, fibrinolysis inhibitors. S-Composition pharmaceutique caractérisée en ce qu'elle eontieDt une quantité efficace du médicament selon l'une quelconque des revendications précédentes en association avec un véhicule pEarma- ceutique ment acceptable.  S-Pharmaceutical composition, characterized in that it contains an effective amount of the medicament according to any one of the preceding claims in combination with a pharmacologically acceptable vehicle.
FR8503965A 1985-03-18 1985-03-18 BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS Expired FR2578745B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR8503965A FR2578745B1 (en) 1985-03-18 1985-03-18 BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS
PCT/FR1986/000089 WO1986005399A1 (en) 1985-03-18 1986-03-17 Pharmaceutical preparations or blood fluidification
AU56257/86A AU5625786A (en) 1985-03-18 1986-03-17 Pharmaceutical preparations or blood fluidification
EP86901898A EP0215876A1 (en) 1985-03-18 1986-03-17 Pharmaceutical preparations or blood fluidification

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8503965A FR2578745B1 (en) 1985-03-18 1985-03-18 BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS

Publications (2)

Publication Number Publication Date
FR2578745A1 true FR2578745A1 (en) 1986-09-19
FR2578745B1 FR2578745B1 (en) 1989-05-12

Family

ID=9317296

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8503965A Expired FR2578745B1 (en) 1985-03-18 1985-03-18 BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS

Country Status (4)

Country Link
EP (1) EP0215876A1 (en)
AU (1) AU5625786A (en)
FR (1) FR2578745B1 (en)
WO (1) WO1986005399A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719791A2 (en) * 1994-12-26 1996-07-03 Tobishi Pharmaceutical Co., Ltd. Medicaments for the treatment of restenosis and arterial sclerosis
EP0750912A3 (en) * 1995-06-28 1998-01-07 Tobishi Pharmaceutical Co., Ltd. Batroxobin containing medicaments for the treatment or prophylaxis of ischemia-reperfusion injury

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123001A (en) * 1998-01-20 1998-12-06 Shulov Inst For Venom Research Analgesic fraction from snake venom and pharmaceutical compositions containing it
US7985428B2 (en) * 2004-08-16 2011-07-26 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Method and composition for modulation of systemic inflammatory responses syndrome (SIRS)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157593A (en) * 1967-01-26 1969-07-09 Expl De Marques Et Brevets S E Pharmaceutical Composition Containing Detoxicated Snake Venom.
FR2222083A1 (en) * 1973-03-22 1974-10-18 Fontaine Michel
FR2487201A2 (en) * 1980-03-24 1982-01-29 Pasteur Institut Immunological agent prepn. by chemically bonding antigen to lymphocyte - using glutaraldehyde or benzoquinone as linking agent e.g. tetanus, diphtheria, leukaemia vaccines, hyperimmune serums for analysis etc.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157593A (en) * 1967-01-26 1969-07-09 Expl De Marques Et Brevets S E Pharmaceutical Composition Containing Detoxicated Snake Venom.
FR2222083A1 (en) * 1973-03-22 1974-10-18 Fontaine Michel
FR2487201A2 (en) * 1980-03-24 1982-01-29 Pasteur Institut Immunological agent prepn. by chemically bonding antigen to lymphocyte - using glutaraldehyde or benzoquinone as linking agent e.g. tetanus, diphtheria, leukaemia vaccines, hyperimmune serums for analysis etc.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719791A2 (en) * 1994-12-26 1996-07-03 Tobishi Pharmaceutical Co., Ltd. Medicaments for the treatment of restenosis and arterial sclerosis
EP0719791A3 (en) * 1994-12-26 1996-12-18 Tobishi Pharmaceutical Co Medicaments for the treatment of restenosis and arterial sclerosis
CN1090028C (en) * 1994-12-26 2002-09-04 东菱药品工业株式会社 Medicine for treatment of restenosis and arteriosclerosis
EP0750912A3 (en) * 1995-06-28 1998-01-07 Tobishi Pharmaceutical Co., Ltd. Batroxobin containing medicaments for the treatment or prophylaxis of ischemia-reperfusion injury

Also Published As

Publication number Publication date
FR2578745B1 (en) 1989-05-12
EP0215876A1 (en) 1987-04-01
AU5625786A (en) 1986-10-13
WO1986005399A1 (en) 1986-09-25

Similar Documents

Publication Publication Date Title
Pal et al. Snake venom as therapeutic agents: from toxin to drug development
CA1330299C (en) Composition of anticoagulants
AU2008203028B2 (en) Pharmaceutically stable hemostatic compositions
US6303112B1 (en) Enriched platelet wound healant
US4478829A (en) Pharmaceutical preparation containing purified fibronectin
US6524568B2 (en) Enriched platelet wound healant
Sherry et al. Studies on the fibrinolytic enzyme of human plasma
JPH07505123A (en) Reconstituted platelet membrane vesicles
JPS62174023A (en) Anticoagulant substance, production thereof and anticoagulant agent containing said substance as active ingredient
FR2578745A1 (en) BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS
Menon et al. Complications of hemotoxic snakebite in India
JPS6042207B2 (en) Method for extracting plasminogen-type active compounds from placenta
AU644196B2 (en) Lipoprotein removal by soluble enzymes
US4729893A (en) Enteric encapsulation of ancrod for oral administration
AU768543B2 (en) Improved enriched platelet wound healant
Sani et al. Inhibition of snake venom enzymes and antivenom adjuvant effects of Azadirachta indica A. Juss.(Meliaceae) leaf extracts
CN1222310C (en) Preparation for administration of hepatocyte growth factor
US4154656A (en) Method for determining the fibrinogen content of physiological liquid
Menarim et al. Bone marrow mononuclear cells for joint therapy: The role of macrophages in inflammation resolution and tissue repair
JP2894224B2 (en) Fibrinogen preparation and kit for preparing fibrin glue using the same
RU2141819C1 (en) Ointment with human leukocytic interferon "interon"
Darla Snake Bite Induced Acute Kidney Injury and its Outcome-A Case Series Study
JP4694709B2 (en) Production inhibitor of endogenous cannabis substances
JPH0296536A (en) Dry plasminogen pharmaceutical
Bathrinarayanan A Study on Profile Snake bite induced Acute Kidney Injury and Outcome

Legal Events

Date Code Title Description
ST Notification of lapse
AR Application made for restoration
BR Restoration of rights
ST Notification of lapse